Position in TGTX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$205,915
New position
Shares Held
3,748
first reported quarter
Ownership
0.002%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#318
of 425 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Essex Financial Services, Inc. holds $1,755,786 across 7 Biotechnology names. TGTX ranks #5 (11.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
840 | $417,253 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
644 | $401,559 | |
| 3 | INCY |
Incyte Corp
|
2,924 | $331,464 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
866 | $260,691 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
This page
|
3,748 | $205,915 | |
| 6 | CRMD |
CorMedix Inc.
|
11,835 | $92,904 | |
| 7 | CGTX |
Cognition Therapeutics Inc
|
40,000 | $46,000 |
All Filings in TGTX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $205,915 | 3,748 | Shares | Sole | 2026-08-10 | |
| No filing history on record for this holder in this stock. | ||||||